TickerFacts.

A business in context

LYEL research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-22 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-10-12 · 0002150331-26-000003

  2. 4 · Ownership change

    Report date 2026-09-10 · 0002150331-26-000002

  3. 4 · Ownership change

    Report date 2026-09-10 · 0001959742-26-000003

  4. 8-K · Current report

    Report date 2026-09-10 · 0001193125-26-387890 · Items 8.01,9.01

  5. 4 · Ownership change

    Report date 2026-08-21 · 0001907345-26-000006

  6. 4 · Ownership change

    Report date 2026-08-21 · 0001866154-26-000006

  7. 4 · Ownership change

    Report date 2026-08-21 · 0001327111-26-000006

  8. 4 · Ownership change

    Report date 2026-08-10 · 0002095702-26-000005

  9. 4 · Ownership change

    Report date 2026-08-10 · 0001907345-26-000004

  10. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001628280-26-054367

  11. 8-K · Current report

    Report date 2026-08-06 · 0001628280-26-054330 · Items 2.02,9.01

  12. 8-K · Current report

    Report date 2026-06-10 · 0001193125-26-271071 · Items 5.07

  13. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001628280-26-031284

  14. 8-K · Current report

    Report date 2026-05-06 · 0001628280-26-031269 · Items 2.02,9.01

  15. DEF 14A · Proxy statement

    Report date 2026-06-10 · 0001140361-26-016686

  16. 10-K · Annual report

    Report date 2025-12-31 · 0001628280-26-017253

  17. 8-K · Current report

    Report date 2026-03-12 · 0001628280-26-017244 · Items 2.02,9.01

  18. 8-K · Current report

    Report date 2026-03-06 · 0001193125-26-097615 · Items 5.02,9.01

  19. 8-K · Current report

    Report date 2025-12-07 · 0001193125-25-310469 · Items 8.01

  20. 8-K · Current report

    Report date 2025-12-03 · 0001193125-25-309621 · Items 5.03,9.01

  21. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001628280-25-051619

  22. 8-K · Current report

    Report date 2025-11-12 · 0001628280-25-051603 · Items 2.02,9.01

  23. 8-K · Current report

    Report date 2025-11-06 · 0001193125-25-273269 · Items 1.01,3.02,7.01,9.01

  24. 8-K · Current report

    Report date 2025-10-31 · 0001193125-25-261753 · Items 5.02

  25. 8-K · Current report

    Report date 2025-09-15 · 0001193125-25-205020 · Items 5.02

  26. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001806952-25-000008

  27. 8-K · Current report

    Report date 2025-08-12 · 0001806952-25-000007 · Items 2.02,9.01

  28. 8-K · Current report

    Report date 2025-07-24 · 0001193125-25-164853 · Items 1.01,3.02,7.01,9.01

  29. 8-K · Current report

    Report date 2025-06-20 · 0001193125-25-148897 · Items 3.02

  30. 8-K · Current report

    Report date 2025-06-17 · 0001193125-25-141795 · Items 8.01

  31. 8-K · Current report

    Report date 2025-06-09 · 0001193125-25-137853 · Items 5.02

  32. 8-K · Current report

    Report date 2025-05-27 · 0001193125-25-129448 · Items 3.03,9.01

  33. 8-K · Current report

    Report date 2025-05-15 · 0001193125-25-123970 · Items 5.07

  34. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001628280-25-025135

  35. 8-K · Current report

    Report date 2025-05-13 · 0001628280-25-025128 · Items 2.02,9.01

  36. DEF 14A · Proxy statement

    Report date 2025-05-15 · 0001140361-25-014721

  37. 8-K · Current report

    Report date 2025-03-27 · 0001193125-25-070521 · Items 2.05,5.02,7.01

  38. 10-K · Annual report

    Report date 2024-12-31 · 0001628280-25-011978

  39. 8-K · Current report

    Report date 2025-03-11 · 0001628280-25-011960 · Items 2.02,9.01

  40. 8-K · Current report

    Report date 2025-01-23 · 0001193125-25-012249 · Items 3.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 10 transaction rows10SGrant / award: 1 transaction rows1AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

14 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-09-10
2026-09-10
Aguirre Jarrad MattieuA · Grant / award
Acquired
Option (right to buy)
Derivative security
47500.00.0
2026-09-10
2026-09-10
Shook DavidS · Sale
Disposed
Common Stock500.012.7
2026-08-21
2026-08-25
Lee Gary K.S · Sale
Disposed
Common Stock1457.015.54
2026-08-21
2026-08-25
Hill Stephen J.S · Sale
Disposed
Common Stock989.015.54
2026-08-21
2026-08-25
Seely LynnS · Sale
Disposed
Common Stock9589.015.54
2026-08-10
2026-08-11
Bulis Veronica SanchezS · Sale
Disposed
Common Stock621.014.34
2026-08-10
2026-08-11
Lee Gary K.S · Sale
Disposed
Common Stock131.014.34
2026-08-10
2026-08-11
Hill Stephen J.S · Sale
Disposed
Common Stock89.014.34
2026-08-10
2026-08-11
Seely LynnS · Sale
Disposed
Common Stock390.014.34
2026-07-27
2026-07-27
Innovative Cellular Therapeutics Holdings LtdJ · Other (see filing)
Disposed
Common Stock44000.00.0
2026-07-27
2026-07-27
Innovative Cellular Therapeutics Holdings LtdJ · Other (see filing)
Disposed
Common Stock38500.00.0
2026-07-17
2026-07-20
Innovative Cellular Therapeutics Holdings LtdS · Sale
Disposed
Common Stock10.013.7
2026-07-16
2026-07-17
Innovative Cellular Therapeutics Holdings LtdS · Sale
Disposed
Common Stock10.013.73
2026-06-29
2026-07-01
Innovative Cellular Therapeutics Holdings LtdJ · Other (see filing)
Disposed
Common Stock76000.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001806952Lyell Immunopharma, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names

    Revenue in constant purchasing power

    USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

    Year endedReported USD revenueCPI-adjusted USD revenue
    2024-12-31$61.0K$65.5K
    2023-12-31$130.0K$143.7K
    2022-12-31$84.68M$97.48M
    2021-12-31$10.65M$13.24M
    2020-12-31$7.76M$10.10M
    2019-12-31$657.0K$865.8K

    Bureau of Labor Statistics · retrieved 2026-10-22 · 9 selected series; gaps remain missing

    Explore the CPI history ↗